Suggested remit: To appraise the clinical and cost effectiveness of netarsudil-latanoprost within its marketing authorisation for treating open-angle glaucoma or ocular hypertension.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 1363

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Stakeholders

Companies sponsors Santen (netarsudil-latanoprost)
  Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Glaucoma UK
Professional groups Royal College of Opthalmologists
  Royal College of Physicians
Comparator companies AbbVie (bimatoprost, brimonidine tartrate, levobunolol hydrochloride, timolol maleate) - confidentiality agreement signed, participating
  Accord (bimatoprost, brinzolamide, dorzolamide, latanoprost, timolol maleate, travoprost) – confidentiality agreement not signed, not participating
  Advanz Pharma (acetazolamide) – confidentiality agreement not signed, not participating
  Aspire Pharma (bimatoprost, brinzolamide, dorzolamide, timolol maleate, travoprost) – confidentiality agreement not signed, not participating
  Bausch & Lomb UK (dorzolamide, pilocarpine hydrochloride/nitrate, timolol maleate) – confidentiality agreement not signed, not participating
  Brown & Burk UK (dorzolamide, timolol maleate) – confidentiality agreement not signed, not participating
  Essential Pharma (apraclonidine) – confidentiality agreement not signed, not participating
  FDC International (betaxolol, brimonidine tartrate, dorzolamide, latanoprost, timolol maleate) – confidentiality agreement not signed, not participating
  Galderma (brimonidine tartrate) – confidentiality agreement not signed, not participating
  Glenmark Pharmaceuticals (dorzolamide) – confidentiality agreement not signed, not participating
  Immedica (betaxolol) – confidentiality agreement not signed, not participating
  Kent Pharmaceuticals (dorzolamide, latanoprost, timolol maleate) – confidentiality agreement not signed, not participating
  Martindale Pharma (dorzolamide, latanoprost, pilocarpine hydrochloride/nitrate, timolol maleate) – confidentiality agreement not signed, not participating
  Medicom Healthcare (latanoprost) – confidentiality agreement not signed, not participating
  Merus Labs Luxco II S.à R.L (pilocarpine hydrochloride/nitrate) – confidentiality agreement not signed, not participating
  Mylan (bimatoprost, brinzolamide, timolol maleate, latanoprost, travoprost) – confidentiality agreement not signed, not participating
  Neon Healthcare (bimatoprost, latanoprost, timolol maleate) – confidentiality agreement not signed, not participating
  Novartis (apraclonidine, betaxolol, brimonidine tartrate, brinzolamide, timolol maleate, travoprost) – confidentiality agreement not signed, not participating
  Sandoz (bimatoprost, brinzolamide, timolol maleate, travoprost) – confidentiality agreement not signed, not participating
  Santen UK (dorzolamide, tafluprost, timolol maleate)
  Thea Pharmaceuticals (latanoprost, timolol maleate) – confidentiality agreement not signed, not participating
  Thornton & Ross (brinzolamide, timolol maleate) – confidentiality agreement not signed, not participating
  Viatris (latanoprost) – confidentiality agreement not signed, not participating
  Zentiva (brinzolamide, dorzolamide, latanoprost, timolol maleate) – confidentiality agreement not signed, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
Relevant research groups National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
08 February 2024 Committee meeting
04 May 2023 The timelines for this appraisal are now confirmed. The first committee meeting will be held on 12 December 2023.
05 April 2023 Following communications with the company, the timelines for this appraisal are now to be confirmed.
10 February 2023 Invitation to participate
10 February 2023 In progress. Invitation to participate issued.
13 January 2022 Please note that following on from information received from the company the timelines for this appraisal are to be confirmed. NICE will continue to monitor the situation and will update interested parties as and when the situation changes.
08 November 2021 - 06 December 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 September 2020 - 26 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual